DUBLIN, Jan. 25, 2024 /PRNewswire/ -- The 'Precision Cancer Diagnostic Test Market Report 2024-2034' has been added to  ResearchAndMarkets.com's offering.

都柏林，2024年1月25日/PRNewswire/——ResearchAndMarkets.com的产品中增加了“2024-2034年精准癌症诊断测试市场报告”。

World revenue for the Precision Cancer Diagnostic Test Market is forecast to surpass US$ 12.09 billion in 2024, with strong revenue growth through to 2034.

预计2024年，精准癌症诊断测试市场的全球收入将超过120.9亿美元，到2034年，收入将强劲增长。

Increasing Adoption of Liquid Biopsies Propels Market Growth

液体活组织检查的日益采用推动了市场增长

The increasing adoption of liquid biopsies in cancer diagnosis has significantly intensified market competitiveness, with companies actively entering this domain viewed as key drivers of clinical advancements. LabCorp's introduction of a novel blood test in June 2023 for detecting cancer-related biomarkers exemplifies this trend, potentially expediting effective treatments..

在癌症诊断中越来越多地采用液体活检，大大增强了市场竞争力，公司积极进入这一领域，被视为临床进步的关键驱动因素。LabCorp于2023年6月推出了一种新的血液检测方法，用于检测与癌症相关的生物标志物，这一趋势就是例证，有可能加速有效的治疗。。

Liquid biopsy, particularly valuable for those unable to undergo tissue biopsies, is gaining traction, notably in diagnosing advanced and metastatic cancer cases. Breakthroughs, such as the detection of cancer in diverse bodily fluids through liquid biopsy in March 2022, highlight the technology's expanding applications.

液体活检，对于那些无法进行组织活检的人来说尤其有价值，正在获得牵引力，特别是在诊断晚期和转移性癌症病例方面。突破，例如2022年3月通过液体活检检测多种体液中的癌症，突显了该技术不断扩大的应用。

The ongoing development of non-invasive liquid biopsies focusing on circulating tumor DNA and other markers holds promise for transforming cancer diagnostics by enabling real-time monitoring and early detection. Industry efforts to integrate liquid biopsy with advanced AI technologies, as seen in collaborations like GC Genome Corporation with KAIST, underscore the commitment to enhancing DNA mutation analysis..

专注于循环肿瘤DNA和其他标志物的非侵入性液体活检的持续发展有望通过实现实时监测和早期检测来改变癌症诊断。业界将液体活检与先进的人工智能技术相结合的努力，如GC Genome Corporation与KAIST的合作所见，强调了加强DNA突变分析的承诺。。

Noteworthy company initiatives, including Qiagen's acquisition of Verogen and BillionToOne's precise liquid biopsy device launch, highlights the industry's focus on growth, technological advancements, and product innovation, driving market expansion.

值得注意的公司举措，包括Qiagen收购Verogen和十亿通精密液体活检设备的推出，突显了行业对增长、技术进步和产品创新的关注，推动了市场扩张。

Challenges Posed by High Cost of Precision Cancer Diagnostic Test

精确癌症诊断测试的高成本带来的挑战

Precision cancer diagnostic tests utilize advanced technologies, such as next-generation sequencing (NGS) or mass spectrometry, which can be associated with high costs, posing challenges for accessibility, especially in resource-constrained regions.

精确的癌症诊断测试利用了先进的技术，例如下一代测序（NGS）或质谱法，这可能与高成本相关，对可及性提出了挑战，尤其是在资源有限的地区。

The elevated expenses linked to precision cancer diagnostics may act as a hindrance to market growth, restricting patient access to these advanced diagnostic tools. Despite the significant advantages offered by precision cancer diagnostics, including more accurate diagnoses and personalized treatment plans, the financial implications associated with these tests presents a formidable challenge for both healthcare systems and patients.

与精确癌症诊断相关的费用上涨可能会阻碍市场增长，限制患者使用这些先进的诊断工具。尽管精准癌症诊断具有显着优势，包括更准确的诊断和个性化治疗计划，但与这些测试相关的财务影响对医疗保健系统和患者来说都是一个巨大的挑战。

For example, the FoundationOne CDx, priced at approximately US$5,800.0 per biopsy, delivers valuable information for treatment decisions but can impose a substantial financial burden on patients and healthcare systems..

例如，FoundationOne CDx每活检定价约5800.0美元，为治疗决策提供了有价值的信息，但可能给患者和医疗保健系统带来巨大的经济负担。。

Guardant360, a liquid biopsy test by Guardant Health analyzing circulating tumor DNA, comes with a cost ranging from US$5,000 to US$6,500 per biopsy. While liquid biopsies are less invasive than tissue biopsies, their pricing remains a concern, potentially limiting access for certain patients, particularly those lacking comprehensive insurance coverage, and leading to potential delays in diagnosis and treatment decisions..

Guardant360是Guardant Health分析循环肿瘤DNA的液体活检测试，每次活检的费用从5000美元到6500美元不等。虽然液体活检比组织活检具有更小的侵入性，但其定价仍然是一个问题，可能会限制某些患者的进入，特别是那些缺乏全面保险的患者，并导致诊断和治疗决策的潜在延误。。

Key Market Dynamics

主要市场动态

Market Driving Factors

市场驱动因素

Advancements in Genomic Research

基因组研究进展

High Demand for Personalized Healthcare

个性化医疗的高需求

Rising Prevalence of Cancer

癌症患病率上升

Market Restraining Factors

市场制约因素

Regulatory Hurdles

监管障碍

High Cost of Precision Cancer Diagnostic Tests

精确癌症诊断测试的高成本

Market Opportunities

市场机会

Integration of AI and Machine Learning for Cancer Diagnosis

人工智能和机器学习在癌症诊断中的集成

Rising Adoption of Liquid Biopsies

液体活组织检查的采用率上升

Forecasts to 2034 and other analyses reveal commercial prospects

对2034年的预测和其他分析揭示了商业前景

In addition to revenue forecasting to 2034, the new study provides you with recent results, growth rates, and market shares.

除了2034年的收入预测之外，这项新研究还为您提供了最新的结果、增长率和市场份额。

You will find original analyses, with business outlooks and developments.

您将找到原始分析，以及商业前景和发展。

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising precision cancer diagnostic test prices and recent developments.

发现定性分析（包括市场动态、驱动因素、机会、限制和挑战）、成本结构、精确癌症诊断测试价格上涨的影响以及最新发展。

Segments Covered in the ReportProduct & Services Outlook

报告《产品与服务展望》涵盖的细分市场

Products

产品

Services

服务

Test Type

测试类型

Cancer Imaging

癌症成像

Computed Tomography

计算机断层扫描

Magnetic Resonance Imaging

磁共振成像

Digital & Analog Mammography

数字和模拟乳房X光检查

Positron Emission Tomography

正电子发射断层扫描

Digital Breast Tomosynthesis

技术

Molecular Breast Imaging

分子乳腺成像

Others

其他

Molecular Cancer Testing

分子癌症检测

Polymerase Chain Reaction (PCR)

聚合酶链反应（PCR）

Next-Generation Sequencing (NGS)

下一代测序（NGS）

Liquid Biopsies

液体活组织检查

Immunohistochemistry (IHC)

免疫组织化学（IHC）

Fluorescence In Situ Hybridization (FISH)

荧光原位杂交（FISH）

Others

其他

Tumour Marker Immunoassays

肿瘤标志物免疫测定

POC Colon Cancer Tests

POC结肠癌测试

Others

其他

Biopsy Method

活检方法

Liquid Biopsy

液体活检

Tissue Biopsy

组织活检

Application

应用程序

Breast Cancer

乳腺癌

Lung Cancer

肺癌

Colorectal Cancer

结直肠癌

Melanoma

黑色素瘤

Pancreatic Cancer

胰腺癌

Other Cancers

其他癌症

End-user

最终用户

Diagnostic Laboratories

诊断实验室

Hospitals

医院

Cancer Centers and Clinics

癌症中心和诊所

Research Institutions

研究机构

The report also includes profiles for the following leading companies, with a focus on this segment of these companies' operations:

该报告还包括以下领先公司的简介，重点关注这些公司的这一部分业务：

Abbott

雅培

Agilent Technologies, Inc.

安捷伦科技有限公司。

Bayer AG

拜耳公司

bioMerieux SA

bioMerieux SA

F. Hoffmann-La Roche Ltd.

F、 霍夫曼·拉罗氏有限公司。

Illumina, Inc.

Illumina公司。

Myriad Genetics, Inc.

Myriad Genetics公司。

QIAGEN N.V.

QIAGEN N.V。

Siemens Healthineers

西门子Healthineers

Thermo Fisher Scientific

赛默飞世尔科技

The report provides you with the following knowledge:

该报告为您提供了以下知识：

Revenue forecasts to 2034 for Precision Cancer Diagnostic Test Market, 2024 to 2034 Market, with forecasts for product, test type, application, biopsy method, and end-user, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues..

精确癌症诊断测试市场到2034年的收入预测，2024年到2034年的市场，以及对产品、测试类型、应用、活检方法和最终用户的预测，每个预测都是在全球和区域层面上进行的-发现行业的前景，找到最有利可图的投资和收入场所。。

Revenue forecasts to 2034 for five regional and 18 key national markets - See forecasts for the Precision Cancer Diagnostic Test Market, 2024 to 2034 market in North America, Europe, Asia Pacific, Latin America, and MEA. Also includes forecast for the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies..

五个地区和18个主要国家市场到2034年的收入预测-请参阅精准癌症诊断测试市场预测，北美，欧洲，亚太地区，拉丁美洲和MEA 2024年至2034年市场预测。还包括对美国、加拿大、墨西哥、巴西、德国、法国、英国、意大利、中国、印度、日本和澳大利亚等主要经济体市场的预测。。

Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the Precision Cancer Diagnostic Test Market, 2024 to 2034.

成熟公司和寻求进入市场的公司的前景-包括2024年至2034年参与精密癌症诊断测试市场的10家主要公司的公司简介。

For more information about this report visit https://www.researchandmarkets.com/r/5q727n

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/5q727n

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

关于ResearchAndMarkets.com ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。

Media Contact:

媒体联系人：

Research and MarketsLaura Wood, Senior Manager[email protected]  For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

研究与市场高级经理斯拉乌拉·伍德（SlauraWood），E.S.T办公时间电话+1-917-300-0470（美国）/CAN免费电话+1-800-526-8630（GMT办公时间电话+353-1-416-8900 U。S、 传真：646-607-1907传真（美国境外）：+353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

徽标：https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

来源研究和市场